Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.31 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 2/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.30 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | MC4R | P32245 | 1/20 | 0.30 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.30 |
| ▸ | MC3R | P41968 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17014177 | 0.82 | KDM4E (0.39) | KDM4ENAPRTHCAR2GAASMN1; SMN2 | |
| SCHEMBL17014179 | 0.78 | MT-CO1 (0.30) | — | |
| SCHEMBL15660744 | 0.77 | KDM4E (0.41) | KDM4ENAPRTHCAR2GAASMN1; SMN2 | |
| SCHEMBL15660742 | 0.77 | KDM4E (0.41) | KDM4ENAPRTHCAR2GAASMN1; SMN2 | |
| SCHEMBL15661869 | 0.73 | KDM4E (0.33) | KDM4ENAPRTHCAR2GAASMN1; SMN2 | |
| SCHEMBL15661870 | 0.73 | KDM4E (0.33) | KDM4ENAPRTHCAR2GAASMN1; SMN2 | |
| SCHEMBL15294847 | 0.73 | ATM (0.34) | ALDH1A1TSHR | |
| SCHEMBL15294849 | 0.72 | — | — | |
| SCHEMBL15294850 | 0.69 | ALDH1A1 (0.34) | GAASMN1; SMN2ALDH1A1MAPTRAB9A | |
| SCHEMBL17014180 | 0.66 | CTNNB1 (0.42) | KDM4ENAPRTGAASMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9328124-B2 | BACE inhibitors | ELI LILLY AND COMPANY (US) | 2016-05-03 | — | — | US | disclosed |
| US-20150232483-A1 | BACE INHIBITORS | ELI LILLY AND COMPANY | 2015-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150232483-A1 | BACE INHIBITORS | BACE1, BACE2, APP | KDM4E 2782/4885NAPRT 2861/4885HCAR2 1599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.